Company intelligence / Profile preview

Hi-Eisai

Makati City, Metro Manila, Philippines

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Hi-Eisai Pharmaceutical, Inc. is the Philippine subsidiary of the Japanese global pharmaceutical company Eisai Co., Ltd. Established in 1974, the company is dedicated to the marketing and distribution of innovative pharmaceutical products across the Philippines, with a strong focus on neurology, oncology, and gastroenterology. Operating under Eisai's human health care (hhc) philosophy, Hi-Eisai aims to improve the quality of life for patients and their families by providing access to life-changing treatments. Its portfolio includes well-known brands such as Aricept for Alzheimer's disease, Lenvima for various cancers, and Pariet for acid-related disorders.

Therapeutic areas: GastroenterologyNeurologyOncology
Modalities: Small moleculeMonoclonal antibodyBiologic
Industry: Biotech

Partnerships

Merck & Co.Biogen

Beyond the preview

Go deeper on Hi-Eisai.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hi-Eisai.

Explore the full profile